enGenes Products & Services

enGenes-X-press protein & DNA production platform


enGenes-X-press protein & DNA production platform


engenes_Logo_final1

Products & Services | enGenes Biotech GmbH

enGenes Biotech has developed X-press as an optimized solution for the cost-effective production of recombinant protein and plasmid DNA in microbial expression systems.

Leveraged from enGenes’ world-class experience in cutting-edge genetic engineering, combined with a broad expertise in bioprocess engineering, the enGenes-X-press Escherichia coli (E.coli) proprietary technology forms a production platform that delivers substantially higher soluble product yields, easier downstream processing and up to 80% reduction in cost of goods sold (COGS).

enGenes-X-press technology

The X-press technology platform allows recombinant product formation to be decoupled from cell growth, enabling bioprocessing with clear phase separation of biomass growth and product formation.

Using this procedure makes it possible to generate significantly higher specific and volumetric yields compared to the previous state-of-the-art (Escherichia coli BL21 (DE3).

Further, X-press developed bioprocesses are characterized by improved genetic stability, robustness and scalability.

The technology is based on a genetically modified host cell based on the Escherichia coli B-linage (BL21) that allows introduction of standard expression vectors (with T7 promoter) without cumbersome adaptations. The X-press fermentation process can be implemented with standard fed-batch fermentation equipment.

Reprogramming of the host cell is performed by co-expression of a bacteriophage-derived peptide that stops cell division and host mRNA production and at the same time modulates the host cell metabolism for improved soluble, high level protein production.

The technology also allows secretion of proteins targeted to the periplasmic space to the cell free supernatant, thereby allowing a cost-effective manufacturing option comparable to yeast-based expression systems.

The technology is fully scalable from lab to industrial scale (developed process running at >10 m³ scale).

enGenes-X-press example yields

The process advantages of enGenes X-press are borne out by sample protein and other yields:

  • Green fluorescent protein (GFP) = 20 g/L
  • Soluble enzyme (hydrolase) = 13 g/L (cytoplasm)
  • Glycosyltransferase = 1 g/L (cytoplasm)
  • Fab antibody fragment = 250 mg/L (cell supernatant)
  • VHH (variable camelid heavy chain-only) single domain antibody = 1 g/L (cell supernatant)
  • Affinity ligand = 8-10 g/L (cell supernatant)

enGenes-X-press features

The enGenes X-press protein production platform is thus made distinctive by a series of unique characteristics:

  • E. coli based, growth decoupled production system
  • Allowing decoupling of protein/DNA production from cell growth
  • Host cell growth halted at defined cell concentration
  • Protein of interest production triggered
  • Host cell resources used exclusively for product of interest
  • Proprietary IP (PCT/EP2016/059597)

X-press economic benefits

The economic benefits of the enGenes X-press platform extend into production and process efficiencies. They include:

  • Higher product yields
  • Significant yield improvement on previous E. coli BL21 (DE3) ‘gold standard’
  • Enabling secretion of protein to cell supernatant
  • Production of growth-interfering or toxic proteins/plasmids
  • Improved genetic stability due to lack of cell division
  • Continuous manufacturing possible
  • Allowing improved Space/Time/Yield

enGenes-X-press forms a next-generation E. coli expression platform that allows for scalable production of difficult-to-express or even growth-interfering “toxic” recombinant proteins and plasmid DNA at a fraction of previous cost. Patents are pending on X-press technology as a growth-decoupled microbial protein production system.

Resources

Click on enGenes X-press protein production platform for more information.
Click on enGenes Biotech GmbH to contact the company directly.
Click on enGenes-X-press technology platform for more information.

Schematic of enGenes X-press process

Schematic of enGenes X-press process


Supplier Information
Supplier: enGenes Biotech GmbH
Address: Mooslackengasse 17, 1190 Vienna, Austria
Tel: +43 1 93 46 707-0
Website: http://www.engenes.cc


Prokaryotic Protein Expression


Prokaryotic Protein Expression


engenes_Logo_final1

Products & Services | enGenes Biotech GmbH

Overview

enGenes Biotech has developed the prokaryotic protein expression system enGenes-X-press™ as a leading edge microbial protein production system for optimized protein expression.

Growth decoupled expression of proteins in prokaryotes such as Escherichia coli (E. coli) allows enGenes to develop economic, scalable and efficient production processes within short time frames to make unique biotech products commercially viable.

Advantages of enGenes X-Press prokaryotic protein expression

enGenes X-Press offers a modular platform for gene expression and protein production in E. coli and will be expanded to other prokaryotes, notably Bacillus subtilis, in the near future. This forms the basis for a similarly modular suite of enGenes services focused on the expression of difficult-to-express proteins.

The service menu is divided into a series of steps which can be performed either individually or in combination – with customers able to select which steps they actually need. The modular approach allows more scalable and cost-effective manufacturing processes for recombinant proteins.

Thus the enGenes-X-press technology for growth-decoupled protein production forms a next-generation E. coli expression platform that allows for scalable production of difficult-to-express or even “toxic” recombinant proteins at a fraction of their current cost.

enGenes prokaryotic protein expression services

Based on enGenes X-Press technology and method portfolio, enGenes can deliver improved host cell lines, plasmid expression vectors and optimized production processes to maximize bioprocess efficacy.

Customized project plans also responds to individual documentation requirements to support easy technology transfer to clients’ own facilities and quality management systems.

enGenes X-press forms the key building block in a modular system of customer services for gene expression and optimized protein production in E. coli, Bacillus subtilis and other prokaryotes.

These prokaryotic protein expression services, focused on difficult-to-express proteins, are offered as a series of options or ‘steps’ covering all specific demands along the line from gene to protein.

These steps, which can be performed individually or in combination, comprise:

  • Cloning / Vector optimization
  • Generation of expression strain and host cell engineering
  • Feasibility studies for enGenes-X-press technology
  • Upstream- and Downstream process development
  • Production of non-GMP material for research in mg- to g-scale

Along with the regular project updates, clients also receive step-by-step progress reports with detailed documentation to comply with their internal quality systems.

Resources

Click on enGenes prokaryotic protein expression for more information.
Click on enGenes Biotech GmbH to contact the company directly.


Supplier Information
Supplier: enGenes Biotech GmbH
Address: Mooslackengasse 17, 1190 Vienna, Austria
Tel: +43 1 93 46 707-0
Website: http://www.engenes.cc


Optimized Protein Expression in Escherichia coli (E. coli)


Optimized Protein Expression in Escherichia coli (E. coli)


engenes_Logo_final1

Products & Services | enGenes Biotech GmbH

Overview

enGenes Biotech has developed Intellectual Property (IP) and has patents pending on its enGenes-X-press™ technology which forms a growth-decoupled microbial protein production system for optimized protein expression in Escherichia coli (E. coli).

This prokaryotic protein expression system allows enGenes Biotech to offer a range of highly relevant products and services to companies seeking develop cost-effective manufacturing processes for recombinant proteins. Overall, the technology is able to speed-up upstream process development timelines, reduces manufacturing costs through increasing product titers and enables more effective downstream processing due to high specific product yields (“more product with less biomass” due to the growth decoupled technology feature).

enGenes-X-Press optimized protein expression system

The world-leading enGenes-X-press technology for growth-decoupled protein production allows enGenes to develop economic, scalable and efficient production processes within short time frames to make unique biotech products commercially viable. It forms a next-generation E. coli expression platform that allows for scalable production of difficult-to-express or even “toxic” recombinant proteins at a fraction of their current cost. Patents are pending on X-press technology as a growth-decoupled microbial protein production system. enGenes is also developing IP in related research fields, such as continuous bioprocessing, improved plasmid vector expression systems and antibiotic resistance-free plasmid selection for recombinant protein production to complement and assists its enGenes-X-press core technology and to cover all aspects of cutting-edge bioprocessing technologies.

The enGenes-X-press technology has been proven to be fully scalable (current scale established at client’s facility >2000 L) and can be implemented easily into any bioproduction facility.

enGenes protein expression service

Based on this extensive knowledge and method portfolio, enGenes can deliver improved host cell lines, plasmid expression vectors and optimized production processes to maximize overall bioprocess efficacy.

Customized project plans also responds to individual documentation requirements to support easy technology transfer to clients’ own facilities and quality management systems.

enGenes performs and initiates projects at different scales and product life cycle stages. Fermentation scales range from microliter scale, to 30 L lab scale to even pilot scale. Up- and Down-stream processes can be developed from the scratch or existing processes can be re-evaluated and improved to meet expected process economics.

enGenes X-press technology forms the key building block in a modular system of customer services for gene expression and optimized protein production in E. coli and other prokaryotes, such as Bacillus subtilis.

The enGenes optimised protein expression service, focused on difficult-to-express proteins, is divided into a series of steps covering all specific demands along the line from gene to protein.

These steps can be performed either individually or in combination, according to customer preferences and include:

  • Cloning / Vector optimization
  • Generation of expression strain and host cell engineering
  • Feasibility studies for enGenes-X-press technology
  • Upstream and Downstream process development from lab to pilot scale
  • Tech transfer to Contract Manufacturing Organization (CMO) or non-GMP in-house production

Along with the regular project updates, clients also receive step-by-step progress reports with detailed documentation to comply with their internal quality systems.

In the last 5 years enGenes Biotech has developed cost-effective manufacturing solutions for the production of recombinant proteins in E. coli. Obtaining high litres of soluble protein in E. coli can be challenging, especially at grams per litre scale. enGenes has assisted several companies to establish cost-effective manufacturing processes and has generated substantial yield improvements by providing a cutting-edge expression technology and extensive bioprocess know-how and understanding.

Resources

Click on enGenes optimized protein expression in E-Coli for more information.
Click on enGenes Biotech GmbH to contact the company directly.


Supplier Information
Supplier: enGenes Biotech GmbH
Address: Mooslackengasse 17, 1190 Vienna, Austria
Tel: +43 1 93 46 707-0
Website: http://www.engenes.cc


Growth-Decoupled Protein Production – enGenes-X-press™


Growth-Decoupled Protein Production – enGenes-X-press™


engenes_Logo_final1

Products & Services | enGenes Biotech GmbH

To learn more about Growth-Decoupled Protein Production – enGenes-X-press™, please click on the brochure below:

DOWNLOAD BROCHURE

DOWNLOAD BROCHURE

Resources

Click on Growth-Decoupled Protein Production – enGenes-X-press™ for more information.
Click on enGenes Biotech GmbH to contact the company directly.


Supplier Information
Supplier: enGenes Biotech GmbH
Address: Mooslackengasse 17, 1190 Vienna, Austria
Tel: +43 1 93 46 707-0
Website: http://www.engenes.cc


Cost-effective recombinant protein production


Cost-effective recombinant protein production


engenes_Logo_final1

Products & Services | enGenes Biotech GmbH

Overview:

enGenes Biotech has developed customized solutions for the cost-effective production of recombinant proteins in microbial expression systems.

The solutions are leveraged from enGenes’ world-class experience in cutting-edge genetic engineering, combined with a broad expertise in bioprocess engineering, to produce best-in-class protein expression systems.

The company’s unique enGenes-X-press™ Escherichia coli (E.coli) proprietary technology forms a production platform that achieves outstanding yields of soluble and active recombinant protein by reducing biological complexity. This is achieved by decoupling biomass growth from product formation.

Expression services

Internationally recognized scientists founded enGenes Biotech to operate in the field of microbial-based protein expression, based on their extensive track-record of scientific publications, patents and a strong understanding for the requirements of the biotech industry built up over years of international cooperation.

Based on this extensive knowledge and method portfolio, enGenes can deliver improved host cell lines, plasmid expression vectors and optimized production processes to maximize bioprocess efficacy and to enable most cost-effective manufacturing.

Customized project plans also responds to individual documentation requirements to support easy technology transfer to clients’ own facilities and quality management systems.

These services are designed to adequately cover all specific demands along the line from gene to protein, with options that include:

  • Cloning / Vector optimization
  • Generation of expression strain and host cell engineering
  • Bioprocess development and bioprocess optimization (USP & DSP)
  • Establishing of purification protocol and final purification
  • Non-GMP mg- to g-scale production of purified proteins
  • Feasibility studies for the proprietary enGenes-X-press™ technology

Technologies;

enGenes-X-press™ constitutes the next-generation E. coli expression platform that allows for scalable production of difficult-to-express or even “toxic” recombinant proteins at a fraction of their current cost. Patents are pending on X-press technology as a growth-decoupled microbial protein production system.

In addition, enGenes is also developing IP in the following research fields:

  • Improved plasmid vector expression systems
  • Antibiotic resistance-free plasmid selection for the production of recombinant proteins

Applications

enGenes expression products and services are highly relevant for companies with interest in developing cost-effective manufacturing processes for recombinant proteins. The world-leading X-press technology for growth-decoupled protein production allows enGenes to develop economic, scalable and efficient production processes within short time frames to enhance the commercial success of unique products.

Prokaryotic protein expression in E.coli

enGenes offers a modular system of customer services for gene expression and protein production in Escherichia coli and other prokaryotes (e.g. Bacillus subtilis). The prokaryotic expression service, focused on the expression of difficult-to-express proteins, is divided into a customer menu of steps that include:

  • Design & engineering
  • Feasibility studies for research and proof-of-concept studies (POC)
  • Bioprocess development and optimization
  • Non-GMP pilot production (mg- to g-scale)
  • Process transfer to CMO

These steps can be performed either individually or in combination, allowing clients to tailor the process to individual requirements.

Resources

Click on Recombinant protein expression and production for more information.
Click on enGenes Biotech GmbH to contact the company directly.

DSC_3747


Supplier Information
Supplier: enGenes Biotech GmbH
Address: Mooslackengasse 17, 1190 Vienna, Austria
Tel: +43 1 93 46 707-0
Website: http://www.engenes.cc